Document is current
Any future updates will be listed below
-
Authors
Rakshasa-Loots, Arish Mudra
Steyn, Christina
Swiffen, Duncan
Marwick, Katie F. M.
Semple, Robert K.
Reynolds, Rebecca M.
Burgess, Karl
Lawrie, Stephen M.
Lightman, Stafford L.
Luz, Saturnino
Smith, Daniel J.
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/Z503563/1)
- License Information
-
More Information
Article History
Received: 27 January 2025
Accepted: 5 February 2025
First Online: 13 February 2025
Declarations
:
: This study will be carried out in accordance with internationally recognised standards for ethical research and the Declaration of Helsinki. All participants will provide written informed consent to take part in the study. This study has received ethical approval from the NHS North of Scotland Research Ethics Committee (1) (REC reference: 24/NS/0138).
: Not applicable.
: RKS has received consulting fees from Astra Zeneca and Alnylam, and speaking fees from Novo Nordisk, Eli Lilly, and Amryt, all relating to severe insulin resistance and/or lipodystrophy. SML has been paid to give an educational talk on cognition in schizophrenia to employees of Kynexis. SLL is a cofounder of Dynamic Therapeutics.
